ANI Pharmaceuticals (ANIP) Earnings Date & Reports

Key Takeaways

• Total net revenues rose 27.6% year over year to $290.8 million, topping consensus estimates.
• Adjusted non-GAAP earnings per share (EPS) came in at $2.70, beating analyst estimates and up from $2.04 a year earlier.
• The Rare Disease segment grew 35.8%, led by Cortrophin Gel (up 36.1%) and ILUVIEN (up 34.1%).
• ANI lowered its full-year Cortrophin Gel revenue guidance to $480 million–$500 million, citing specialty-pharmacy capacity constraints.
• The company announced a $560 million all-cash offer to acquire Egetis Therapeutics and its rare-disease therapy EMCITATE.
• Full-year 2026 adjusted non-GAAP diluted EPS guidance was raised to $9.37–$9.71.
• For additional detail on ANIP's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages.
• Explore Trending AI Robots for AI-driven trading ideas and market signals.

Earnings Context and Why It Matters

ANI Pharmaceuticals has been repositioning itself as a leading rare-disease company, using cash flow from its generics and branded portfolio to fund higher-margin specialty therapies. This third-quarter report matters because it tests that transformation at a critical juncture: Cortrophin Gel, the company's flagship rare-disease product, is expanding into acute gouty arthritis, while generics continue to outperform. The results also arrive alongside a major strategic move, the proposed acquisition of Egetis Therapeutics. For investors, the quarter offers a read on demand momentum, margin expansion, and whether the company can convert strong rare-disease demand into revenue amid operational capacity constraints.

Reported Results

For the third quarter of 2026, ANI Pharmaceuticals reported total net revenues of $290.8 million, a 27.6% increase year over year and above consensus estimates of roughly $281 million–$286 million. Adjusted non-GAAP diluted EPS was $2.70, exceeding analyst expectations of approximately $2.18–$2.22 and up from $2.04 in the prior-year period. On a GAAP basis, net income available to common shareholders was $35.1 million, or $1.51 per diluted share, compared with $1.13 a year earlier. Adjusted non-GAAP EBITDA rose 39.8% to $83.3 million.

Segment results were mixed. Rare Disease net revenues increased 35.8% to $160.9 million, driven by Cortrophin Gel (up 36.1% to $138.7 million) and ILUVIEN (up 34.1% to $22.3 million). Generic pharmaceutical product revenues grew 10.7% to $104.5 million, while Brands declined 6.5% to $10.0 million. The company also recognized $11.5 million under the Harmony Agreement.

On guidance, ANI tightened its total revenue range to $1.085 billion–$1.125 billion, lowered Cortrophin Gel guidance to $480 million–$500 million, and raised adjusted non-GAAP diluted EPS guidance to $9.37–$9.71.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, supporting a more systematic approach to market research. Explore the AI Screener to refine your watchlist and uncover potential opportunities aligned with your strategy.

Market Reaction and Investor Sentiment

Despite the top- and bottom-line beat, investor reaction reflected a more cautious read of the quarter. The stock traded lower on the day of the report, weighed by the reduced Cortrophin Gel revenue guidance and the disclosure that specialty-pharmacy network capacity slowed conversion of new gout cases into patients on therapy. The proposed $560 million Egetis Therapeutics acquisition, which is expected to be dilutive to adjusted non-GAAP EPS in year one, also factored into sentiment. However, the generics outperformance and the raised full-year EPS outlook provided a counterbalance, suggesting that investors are balancing near-term execution friction against a broadening rare-disease pipeline.

Forward Outlook and Key Factors to Monitor

The most immediate item to watch is whether ANI can expand its specialty-pharmacy network quickly enough to convert strong Cortrophin Gel demand into revenue. Management noted that new gout patient cases doubled quarter over quarter and that new prescribers rose about 67%, but revenue conversion lagged. Improving this throughput will be central to hitting the revised Cortrophin guidance and sustaining rare-disease growth.

Second, the Egetis Therapeutics acquisition adds a new growth driver in EMCITATE, the first approved treatment in the U.S. and Europe for peripheral thyrotoxicosis associated with MCT8 deficiency. Investors will track deal closing, expected in late 2026 or early 2027, as well as the early U.S. commercial launch that began in late October.

Finally, watch the generics business, which continues to outperform and provides the cash flow that funds rare-disease investment. Margin trends, the pace of new product launches, and capital-allocation decisions, including share repurchases, will all shape how the market evaluates ANI's transformation over the coming quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations